FDA Disclaimer
After a serial of Double-Blind Tests, the FDA concluded the method bears no utility for Obesity therapy and directed pharmaceutical suppliers to include this finding in all required product information leaflets.
After a serial of Double-Blind Tests, the FDA concluded the method bears no utility for Obesity therapy and directed pharmaceutical suppliers to include this finding in all required product information leaflets.